Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Immunovant Sciences GmbH
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Any participant who has completed Study IMVT-1401-2401
Female participants of childbearing potential must agree to use a highly effective method of birth control
Female participants must agree not to donate eggs throughout the study and for 90 days after the final study treatment administration
Male participants must agree to use 1 highly effective contraception method with partners of childbearing potential throughout the study period and for 90 days after the final study treatment administration
Male participants must agree not to donate sperm throughout the study period and for 90 days after the final study treatment administration
Agree not to participate in another interventional study while on treatment
You may not be if
Participant has any medical condition (acute or chronic illness) or psychiatric condition, including autoimmune disease or neurologic disease other than CIDP, or known history of drug or alcohol abuse that, in the opinion of the Investigator, could jeopardize the participant's ability to participate in this study, compromise accurate assessment of CIDP symptoms or otherwise interfere with the course and conduct of the study.
Participant intends to have a live vaccination during the course of the study or within 7 weeks following the final dose of batoclimab
Participant has an ongoing SAE or a medical condition in the IMVT-1401-2401 study that the Investigator considers putting the participant at a significantly increased risk of participating in Study IMVT-1401-2402
Participant has received Standard of Care therapy for treatment of a relapse in Study IMVT-1401-2401
Note: Other protocol specified criteria may apply.
